
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is well-positioned for future growth as it has a strong customer base and partnerships with big players in the healthcare industry. With a focus on expanding current customers and forming new partnerships, the company is experiencing moderate growth in customer additions and has a healthy backlog of revenue. Furthermore, their goal of reaching profitability by the second half of 2027, with a projected revenue of $109M in 2027, demonstrates the company's potential for financial success in the long term.
Bears say
Sophia Genetics is a healthcare technology company with a new exome product targeting germline diseases, and plans to offer this product for somatic diseases in the future. While the company's land and expand model is showing customer growth, it is not yet profitable and there is no guarantee of future profitability. Overall, SOPH must prove its ability to achieve profitability in the medium term, and its success in the competitive healthcare technology industry remains uncertain.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares